
IN8BIO (INAB) Stock Forecast & Price Target
IN8BIO (INAB) Analyst Ratings
Bulls say
IN8bio Inc. demonstrates a positive financial outlook due to its promising clinical advancements, particularly with the INB-100 candidate, which exhibits significant efficacy in preventing relapse in high-risk acute myeloid leukemia (AML) patients following haploidentical stem cell transplantation. The reported 100% overall survival rate at one year for patients treated with INB-100, compared to the historical average of approximately 70%, underscores the potential impact of this treatment on patient outcomes and market penetration. Additionally, the absence of serious treatment-related adverse events enhances the profile of INB-100, suggesting a favorable risk-benefit ratio that could drive future commercial success as the multi-center expansion study progresses toward completion in 2025.
Bears say
The financial outlook for IN8bio Inc appears negative, primarily due to a recent downward revision of the 12-month price target from $8.00 to $6.00, indicating reduced confidence in the company's future stock performance. Although preclinical studies for INB-619 demonstrate potential therapeutic benefits, there remains uncertainty surrounding the transition from preclinical to clinical stages and the ability to successfully commercialize their product candidates. The reliance on several experimental therapies, coupled with the inherent risks of clinical-stage development, heightens the financial risk associated with investing in IN8bio.
This aggregate rating is based on analysts' research of IN8BIO and is not a guaranteed prediction by Public.com or investment advice.
IN8BIO (INAB) Analyst Forecast & Price Prediction
Start investing in IN8BIO (INAB)
Order type
Buy in
Order amount
Est. shares
0 shares